menu
    • menu

    Company profile for Nicox SA

    NEW Drugs in Dev: 6
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nicox’s portfolio includes three programs in development, all of which are in, or preparing to enter, Phase 2 clinical studies: NCX 470 for reduction of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension; NCX 4251 for patients with acute exacerbations of blepharitis; and NCX 4280 (formerly AC-120) for relief of ocular redness and lid swelling due to morning ocular congestion. NCX 470 is ba...
    Nicox’s portfolio includes three programs in development, all of which are in, or preparing to enter, Phase 2 clinical studies: NCX 470 for reduction of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension; NCX 4251 for patients with acute exacerbations of blepharitis; and NCX 4280 (formerly AC-120) for relief of ocular redness and lid swelling due to morning ocular congestion. NCX 470 is based on our proprietary nitric oxide (NO) donating research platform. NCX 4251 and NCX 4280 are product candidates based on repurposed molecules that have previously been used in other indications and therapeutic areas.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nicox SAFrance Flag
    Country
    Country
    France
    Address
    Address
    Drakkar 2 - Bld D 2405 road Dolines - CS 10313 Sophia Antipolis
    Telephone
    Telephone
    +33 (0) 4 97 24 53 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nicox.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nicox to Present NCX 470 Phase 3 Data at AGS 2026 Meeting
    Nicox to Present NCX 470 Phase 3 Data at AGS 2026 Meeting

    10 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/10/3235013/0/en/Nicox-to-Present-Data-from-NCX-470-Phase-3-Studies-at-American-Glaucoma-Society-AGS-Annual-Meeting-2026.html

    GLOBENEWSWIRE
    10 Feb 2026
    Share Share
    Nicox Announces H1 2026 Conferences and Data Presentations
    Nicox Announces H1 2026 Conferences and Data Presentations

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221299/0/en/Nicox-Announces-Conference-Attendance-in-H1-2026-and-Upcoming-Scientific-Data-Presentations.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Nicox Repays Kreos Debt, Extends Cash Runway Beyond 2027
    Nicox Repays Kreos Debt, Extends Cash Runway Beyond 2027

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212425/0/en/Nicox-Announces-Complete-Repayment-of-Kreos-Capital-Debt-and-Extends-Cash-Runway-Beyond-2027-with-New-Additional-Financing.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Nicox Wraps Up NCX 470 NDA Data Generation For H1 2026 Submission
    Nicox Wraps Up NCX 470 NDA Data Generation For H1 2026 Submission

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3205951/0/en/Nicox-Completes-NCX-470-New-Drug-Application-Key-Data-Generation-for-Submission-as-Planned-in-H1-2026.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Nicox Provides First Half 2025 Financial Results
    Nicox Provides First Half 2025 Financial Results

    23 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/23/3171674/0/en/Nicox-Provides-First-Half-2025-Financial-Results.html

    GLOBENEWSWIRE
    23 Oct 2025
    Share Share
    Nicox’s NCX 470 Shows 12-Month Efficacy in Denali Trial
    Nicox’s NCX 470 Shows 12-Month Efficacy in Denali Trial

    02 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/02/3160086/0/en/Nicox-s-NCX-470-Demonstrates-Sustained-Efficacy-through-12-Months-in-Denali-Clinical-Trial-with-no-new-Safety-Observations.html

    GLOBENEWSWIRE
    02 Oct 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search